Recombinant Interleukin-18 Immunotherapy: A Deep Dive in Targets for Cancer IO

When:  Jul 18, 2022 from 12:00 to 14:00 (CT)
This webinar, the second of the 2022 Targets for Cancer IO: A Deep Dive Series, will discuss the research and clinical findings behind recombinant IL-18 immunotherapy. Basic, clinical and translational researchers in academia and industry and members of the investment community are the target audience of this series.

Moderators:
  • Michael T. Lotze, MD, FACS – Nurix Therapeutics
  • Aaron M. Ring, MD, PhD – Yale University School of Medicine
Faculty:
  • Scott W. Canna, MD - University of Pennsylvania, The Children's Hospital of Philadelphia
  • Simone A. Minnie, PhD - Fred Hutchinson Cancer Research Center

Learn more about the 2022 Targets for Cancer IO: A Deep Dive Series here!

Targets for Cancer IO: A Deep Dive Series is supported, in part, by educational grants from Genmab, US, Inc. and Merck & Co., Inc. (as of 6/6/2022).

#TargetsforCancerImmunotherapyADeepDiveSeminarSeries #NoCEOffered #Industry #Researcher #2022
Event Image

Contact



education@sitcancer.org

Related Content